Latest Protein kinase inhibitor Stories
Fostamatinib at 100mg BID Significantly Improves Rheumatoid Arthritis in Both OSKIRA-2 & OSKIRA-3 SOUTH SAN FRANCISCO, Calif., June 4, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and AstraZeneca AB (AZ) today announced the topline results from OSKIRA-2 and OSKIRA-3, the remaining pivotal Phase 3 clinical trials investigating fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA). In the OSKIRA-2 study of...
DIEPENBEEK, Belgium, June 3, 2013 /PRNewswire/ -- Amakem NV, a clinical stage ophthalmology company, today announces that Dr. Jack Elands, CEO, will present at the Jefferies 2013 Global Healthcare Conference in New York City. Dr. Elands will provide a corporate update and information on Amakem's lead drug candidate, the locally-acting Rho kinase (ROCK) inhibitor AMA0076 which is in Phase 2 development for the treatment of glaucoma. The presentation will take place at...
Two Partnered Oncology Programs to Initiate Clinical Trials SOUTH SAN FRANCISCO, Calif., May 22, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the clinical advancement of three programs in development. The first program is a wholly-owned topical ophthalmic formulation of a JAK/SYK inhibitor, R348, being developed by Rigel as a treatment for dry eye disease. The other two programs are aimed at oncology targets and are being conducted by corporate...
Data Presented at American Society of Clinical Oncology (ASCO) on two Boehringer Ingelheim Phase III Oncology Compounds, Afatinib* and Nintedanib*, Show Progression Free Survival in Patients with Advanced Non-Small Cell Lung Cancer BURLINGTON, ON, May 16, 2013 /CNW/ - New research taking place right here on Canadian soil is shedding light on the nation's number one cancer killer,(i) lung cancer. Boehringer Ingelheim (Canada) Ltd. today announced data from Phase III clinical...
For U.S. Media Only RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced data from two Phase III clinical trials involving two different investigational oncology compounds - afatinib* and nintedanib* - in two distinct patient populations with advanced non-small cell lung cancer (NSCLC). Results from both studies will be presented at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in...
LAUSANNE, Switzerland and SUZHOU, China, April 18, 2013 /PRNewswire/ -- Suzhou Ascepion Pharmaceuticals, Inc. (Ascepion), a Chinese leading biotech company focusing on the discovery and development of world-class molecular targeted innovative drugs and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies, announced today that Debiopharm will support further development in China of Debio 1144, a small molecule in preclinical development...
CAMBRIDGE, Mass., April 4, 2013 /PRNewswire-USNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) today announced that one cohort of a Phase 2 non-small cell lung cancer (NSCLC) study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with erlotinib to treat patients with NSCLC whose disease progressed on an anti-EGFR tyrosine kinase inhibitor (EGFR-TKI). MM-121 is being evaluated in two additional NSCLC cohorts as well as Phase 2 studies for the...
DUBLIN, April 2, 2013 /PRNewswire/ -- Research and Markets) has announced the addition of the "Vascular Endothelial Growth Factor (VEGF) Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013" report to their offering (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis, has been extensively studied and over-expression is seen in many cancers. Today, VEGF is targeted using...
Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides. The therapy may not be effective for all patients, but those with trisomy 8 chromosomal disorder have higher rates of stable disease and respond better to treatment with dasatinib,...
LUXEMBOURG, February 28, 2013 /PRNewswire/ -- Creabilis SA, a late clinical stage European biotechnology company specialising in the development of treatments in dermatology, inflammation and pain, today announces that it has appointed Catherine Moukheibir to its Board of Directors. Catherine has gained a wealth of experience in the pharmaceutical industry and finance in career spanning more than 30 years. She is currently Senior Advisor, Finance and Member of the...
